



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#11/C
NB
06/03/02

Application of: **Yu, et al.**

Application Number: 09/589,288

Group Art Unit: 1646

Filed: June 8, 2000

Examiner: Prasad, S.

Title: **Methods of Treatment Using Antibodies** Atty. Docket No. PF343P3C5
to Neutrokin-alpha (as amended)

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111
WITH STATEMENT UNDER 37 C.F.R. §1.125(b)(1)

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action dated November 6, 2001 (Paper No. 8),
Applicants request that the following amendments and remarks be entered into the above-
identified application. Applicants submit concurrently herewith:

- (a) Version with Markings to Show Changes Made;
- (b) Substitute Specification;
- (c) Version of the Substitute Specification to Show Changes Made;
- (d) A Clean Version of the Entire Set of Pending Claims;
- (e) First Supplemental Information Disclosure Statement Pursuant to 37 C.F.R.
§ 1.56 (with a revised Form PTO/SB/08 and copies of references B6-B9);
- (f) Substitute Sequence Listing in Paper and CRF formats;
- (g) Statements Under 37 C.F.R. §§ 1.825(a) and (b);
- (h) Request for Corrected Filing Receipt, with copy of marked-up Filing
Receipt;
- (i) A Petition for a Three Month Extension of Time with appropriate fee; and
- (j) Fee Transmittal Sheet.

OK to
enter
9/9/02
sep